Prostate-specific antigen and detection of prostate cancer: What we have we learned and what should we recommend for screening?

被引：22

作者：

Amling C.L. ^{[1
]}

机构：

[1] Division of Urology, FOT 1105, University of Alabama at Birmingham, Birmingham, AL 35294

来源：

Current Treatment Options in Oncology | 2006年 / 7卷 / 5期

关键词：

Prostate Cancer; Radical Prostatectomy; National Comprehensive Cancer Network; Prostate Cancer Screening; Prostate Cancer Incidence;

D O I：

10.1007/s11864-006-0001-1

中图分类号：

学科分类号：

摘要：

Prostate-specific antigen (PSA) has become one of the most commonly used cancer clinical tests, and routine PSA-based screening has led to a dramatic increase in prostate cancer detection. A significant downward stage migration has resulted, and a decrease in prostate cancer mortality has also been observed. However, PSA screening remains controversial because there is no definitive proof that it decreases prostate cancer death rates, and there is concern that it may detect a significant number of clinically insignificant cancers. Screening age and interval have been recently questioned, and the best threshold to recommend biopsy has been complicated by new data showing that prostate cancer exists at all PSA levels, even those thought to be "normal" in the past. It is hoped that ongoing prospective screening trials will determine the value of PSA screening. However, until these results are available the controversy will continue, and men will continue to be screened. Copyright © 2006 by Current Science Inc.

引用

页码：337 / 345

页数：8

共 49 条

[1]

Hernandez J., Thompson I.M., Prostate-specific antigen: Review of the validation of the most commonly used cancer biomarker, Cancer, 101, pp. 894-904, (2004)

[2]

Catalona W.J., Smith D.S., Ratliff T.L., Et al., Measurement of prostate-specific antigen in serum as a screening test for prostate cancer, N Engl J Med, 324, pp. 1156-1161, (1991)

[3]

Catalona W.J., Smith D.S., Ratliff T.L., Et al., Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening, JAMA, 270, pp. 948-954, (1993)

[4]

Ross L.E., Coates R.J., Breen N., Et al., Prostate-specific antigen test use reported in the 2000 National Health Interview Survey, Prev Med, 38, pp. 732-744, (2004)

[5]

Gann P.H., Hennekens C.H., Stampfer M.J., A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer, JAMA, 273, pp. 289-294, (1995)

[6]

Punglia R.S., D'Amico A.V., Catalona W.J., Et al., Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen, N Engl J Med, 349, pp. 335-342, (2003)

[7]

Stamey T.A., Johnstone I.M., McNeal J.E., Et al., Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology

[8]

prostate specific antigen cure rates appear constant between 2 and 9 ng/ml, J Urol, 167, pp. 103-111, (2002)

[9]

Oesterling J.E., Jacobsen S.J., Chute C.G., Et al., Serum prostate specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges, JAMA, 270, pp. 860-864, (1993)

[10]

Catalona W.J., Hudson M.A., Scardino P.T., Et al., Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves, J Urol, 152, pp. 2037-2042, (1994)

← 1 2 3 4 5 →